MeiraGTx (NASDAQ:MGTX – Get Free Report) and Tevogen Bio (NASDAQ:TVGN – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, analyst recommendations, earnings, institutional ownership and profitability.
Profitability
This table compares MeiraGTx and Tevogen Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MeiraGTx | -633.05% | -146.38% | -53.05% |
| Tevogen Bio | N/A | -396.07% | 749.97% |
Insider and Institutional Ownership
67.5% of MeiraGTx shares are held by institutional investors. 8.4% of MeiraGTx shares are held by insiders. Comparatively, 56.6% of Tevogen Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MeiraGTx | 0 | 0 | 2 | 0 | 3.00 |
| Tevogen Bio | 0 | 0 | 1 | 0 | 3.00 |
MeiraGTx presently has a consensus price target of $23.50, suggesting a potential upside of 270.66%. Tevogen Bio has a consensus price target of $4.20, suggesting a potential upside of 176.32%. Given MeiraGTx’s higher possible upside, equities research analysts plainly believe MeiraGTx is more favorable than Tevogen Bio.
Risk and Volatility
MeiraGTx has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500. Comparatively, Tevogen Bio has a beta of -1.22, suggesting that its stock price is 222% less volatile than the S&P 500.
Earnings and Valuation
This table compares MeiraGTx and Tevogen Bio”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MeiraGTx | $13.93 million | 35.57 | -$84.03 million | ($1.21) | -5.24 |
| Tevogen Bio | N/A | N/A | -$70,000.00 | N/A | N/A |
Tevogen Bio has lower revenue, but higher earnings than MeiraGTx.
Summary
MeiraGTx beats Tevogen Bio on 6 of the 10 factors compared between the two stocks.
About MeiraGTx
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.
About Tevogen Bio
Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.
Receive News & Ratings for MeiraGTx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MeiraGTx and related companies with MarketBeat.com's FREE daily email newsletter.
